The Prevalence of Appendiceal Tumours in Periappendicular Abscess
Launched by TURKU UNIVERSITY HOSPITAL · Nov 17, 2020
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how common tumors in the appendix are in patients who have a condition called a periappendicular abscess, which is often related to appendicitis. The researchers noticed that a significant number of patients over 40 years old with this condition had tumors. They aim to better understand the prevalence of these tumors and recommend that all patients with a periappendicular abscess, especially those older than 35, undergo a specific type of surgery called interval appendectomy after initial treatment with antibiotics and drainage.
To participate in the trial, patients must have a confirmed periappendiceal abscess through imaging tests like a CT scan or MRI. If you're eligible and join, you can expect to have surgery about 2 to 3 months after your initial treatment. If you’re under 35 and prefer not to have surgery, you will have a follow-up MRI a year later to monitor your condition. This study is important because it aims to ensure that any potential tumors are not missed, especially in older patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • periappendiceal abscess proven by CT, Mri or US
- Exclusion Criteria:
- • patient declines to participate, complicated appendicitis without periappendiceal abscess
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Paulina Salminen, prof, MD
Principal Investigator
Turku University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials